Biotechnological Based Recombinant Protein Vaccines Developed Against Toxoplasmosis
Toxoplasma gondii (T. gondii) that can infect most warm-blooded animals and humans, is an obligate intracellular apicomplexan parasite with a wide host range. About one-third of the world’s population is infected with this parasite. While toxoplasmosis progresses asymptomatically in individuals with...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Galenos Yayinevi
2022-12-01
|
| Series: | Türkiye Parazitoloji Dergisi |
| Subjects: | |
| Online Access: |
http://www.turkiyeparazitolderg.org/archives/archive-detail/article-preview/biotechnological-based-recombinant-protein-vaccine/57299
|
| _version_ | 1797908253191962624 |
|---|---|
| author | Tuğba Karakavuk Ceren Gül Muhammet Karakavuk Aytül Gül Sedef Erkunt Alak Hüseyin Can Cemal Ün Mert Döşkaya Adnan Yüksel Gürüz Aysu Değirmenci Döşkaya |
| author_facet | Tuğba Karakavuk Ceren Gül Muhammet Karakavuk Aytül Gül Sedef Erkunt Alak Hüseyin Can Cemal Ün Mert Döşkaya Adnan Yüksel Gürüz Aysu Değirmenci Döşkaya |
| author_sort | Tuğba Karakavuk |
| collection | DOAJ |
| description | Toxoplasma gondii (T. gondii) that can infect most warm-blooded animals and humans, is an obligate intracellular apicomplexan parasite with a wide host range. About one-third of the world’s population is infected with this parasite. While toxoplasmosis progresses asymptomatically in individuals with a strong immune system, it can cause serious clinical manifestations and death in immunocompromised individuals. The parasite is transmitted to humans through the consumption of water and food contaminated with cat feces, as well as raw or undercooked animal products, congenital infection and blood/organ transplantation. Additionally, T. gondii is often observed in farm animals such as sheep and goats. Clinical manifestations and abortions caused by T. gondii in sheep and goats lead to enormous economic loss worldwide. There is a commercial vaccine against T. gondii, called Toxovax (MSD, New Zealand) that can only be used in sheep. For these reasons, there is a need for innovative T. gondii vaccine that is harmless, easily produced, which can prevent losses and be used in all living things. Advances in immunology, molecular biology, genetic, biotechnology and proteomics bring new perspectives to vaccine studies. Studies in innovative vaccine studies against T. gondii have accelerated with the discovery of new antigens by in vitro screenings, and bioinformatic analyzes, the use of various expression systems and new adjuvant types. Recombinant protein vaccines are biotechnological vaccines that are frequently preferred due to their rapid and easy production in various expression systems, availability of very and high purity products, ease of manipulation and stimulation of both cellular and humoral immune responses. Recombinant protein vaccines, developed by biotechnological methods, are promising tools for providing a protective immune response against toxoplasmosis. In this review, an overview of the parasite complex life cycle, its pathogenesis, humoral and cellular immune responses in the host, and recombinant protein vaccine studies developed against the parasite are presented. |
| first_indexed | 2024-04-10T10:49:51Z |
| format | Article |
| id | doaj.art-5e7c520b44aa4714bb750b5edcfcb359 |
| institution | Directory Open Access Journal |
| issn | 1300-6320 2146-3077 |
| language | English |
| last_indexed | 2024-04-10T10:49:51Z |
| publishDate | 2022-12-01 |
| publisher | Galenos Yayinevi |
| record_format | Article |
| series | Türkiye Parazitoloji Dergisi |
| spelling | doaj.art-5e7c520b44aa4714bb750b5edcfcb3592023-02-15T16:20:10ZengGalenos YayineviTürkiye Parazitoloji Dergisi1300-63202146-30772022-12-0146434235710.4274/tpd.galenos.2022.4163613049054Biotechnological Based Recombinant Protein Vaccines Developed Against ToxoplasmosisTuğba Karakavuk0Ceren Gül1Muhammet Karakavuk2Aytül Gül3Sedef Erkunt Alak4Hüseyin Can5Cemal Ün6Mert Döşkaya7Adnan Yüksel Gürüz8Aysu Değirmenci Döşkaya9 Ege Üniversitesi, Aşı Geliştirme, Uygulama ve Araştırma Merkezi, İzmir, Türkiye Ege Üniversitesi, Aşı Geliştirme, Uygulama ve Araştırma Merkezi, İzmir, Türkiye Ege Üniversitesi, Aşı Geliştirme, Uygulama ve Araştırma Merkezi, İzmir, Türkiye Ege Üniversitesi, Aşı Geliştirme, Uygulama ve Araştırma Merkezi, İzmir, Türkiye Ege Üniversitesi, Aşı Geliştirme, Uygulama ve Araştırma Merkezi, İzmir, Türkiye Ege Üniversitesi, Aşı Geliştirme, Uygulama ve Araştırma Merkezi, İzmir, Türkiye Ege Üniversitesi, Aşı Geliştirme, Uygulama ve Araştırma Merkezi, İzmir, Türkiye Ege Üniversitesi, Aşı Geliştirme, Uygulama ve Araştırma Merkezi, İzmir, Türkiye Ege Üniversitesi, Aşı Geliştirme, Uygulama ve Araştırma Merkezi, İzmir, Türkiye Ege Üniversitesi, Aşı Geliştirme, Uygulama ve Araştırma Merkezi, İzmir, Türkiye Toxoplasma gondii (T. gondii) that can infect most warm-blooded animals and humans, is an obligate intracellular apicomplexan parasite with a wide host range. About one-third of the world’s population is infected with this parasite. While toxoplasmosis progresses asymptomatically in individuals with a strong immune system, it can cause serious clinical manifestations and death in immunocompromised individuals. The parasite is transmitted to humans through the consumption of water and food contaminated with cat feces, as well as raw or undercooked animal products, congenital infection and blood/organ transplantation. Additionally, T. gondii is often observed in farm animals such as sheep and goats. Clinical manifestations and abortions caused by T. gondii in sheep and goats lead to enormous economic loss worldwide. There is a commercial vaccine against T. gondii, called Toxovax (MSD, New Zealand) that can only be used in sheep. For these reasons, there is a need for innovative T. gondii vaccine that is harmless, easily produced, which can prevent losses and be used in all living things. Advances in immunology, molecular biology, genetic, biotechnology and proteomics bring new perspectives to vaccine studies. Studies in innovative vaccine studies against T. gondii have accelerated with the discovery of new antigens by in vitro screenings, and bioinformatic analyzes, the use of various expression systems and new adjuvant types. Recombinant protein vaccines are biotechnological vaccines that are frequently preferred due to their rapid and easy production in various expression systems, availability of very and high purity products, ease of manipulation and stimulation of both cellular and humoral immune responses. Recombinant protein vaccines, developed by biotechnological methods, are promising tools for providing a protective immune response against toxoplasmosis. In this review, an overview of the parasite complex life cycle, its pathogenesis, humoral and cellular immune responses in the host, and recombinant protein vaccine studies developed against the parasite are presented. http://www.turkiyeparazitolderg.org/archives/archive-detail/article-preview/biotechnological-based-recombinant-protein-vaccine/57299 toxoplasma gondiirecombinant protein vaccinesbiotechnologyimmunization |
| spellingShingle | Tuğba Karakavuk Ceren Gül Muhammet Karakavuk Aytül Gül Sedef Erkunt Alak Hüseyin Can Cemal Ün Mert Döşkaya Adnan Yüksel Gürüz Aysu Değirmenci Döşkaya Biotechnological Based Recombinant Protein Vaccines Developed Against Toxoplasmosis Türkiye Parazitoloji Dergisi toxoplasma gondii recombinant protein vaccines biotechnology immunization |
| title | Biotechnological Based Recombinant Protein Vaccines Developed Against Toxoplasmosis |
| title_full | Biotechnological Based Recombinant Protein Vaccines Developed Against Toxoplasmosis |
| title_fullStr | Biotechnological Based Recombinant Protein Vaccines Developed Against Toxoplasmosis |
| title_full_unstemmed | Biotechnological Based Recombinant Protein Vaccines Developed Against Toxoplasmosis |
| title_short | Biotechnological Based Recombinant Protein Vaccines Developed Against Toxoplasmosis |
| title_sort | biotechnological based recombinant protein vaccines developed against toxoplasmosis |
| topic | toxoplasma gondii recombinant protein vaccines biotechnology immunization |
| url |
http://www.turkiyeparazitolderg.org/archives/archive-detail/article-preview/biotechnological-based-recombinant-protein-vaccine/57299
|
| work_keys_str_mv | AT tugbakarakavuk biotechnologicalbasedrecombinantproteinvaccinesdevelopedagainsttoxoplasmosis AT cerengul biotechnologicalbasedrecombinantproteinvaccinesdevelopedagainsttoxoplasmosis AT muhammetkarakavuk biotechnologicalbasedrecombinantproteinvaccinesdevelopedagainsttoxoplasmosis AT aytulgul biotechnologicalbasedrecombinantproteinvaccinesdevelopedagainsttoxoplasmosis AT sedeferkuntalak biotechnologicalbasedrecombinantproteinvaccinesdevelopedagainsttoxoplasmosis AT huseyincan biotechnologicalbasedrecombinantproteinvaccinesdevelopedagainsttoxoplasmosis AT cemalun biotechnologicalbasedrecombinantproteinvaccinesdevelopedagainsttoxoplasmosis AT mertdoskaya biotechnologicalbasedrecombinantproteinvaccinesdevelopedagainsttoxoplasmosis AT adnanyukselguruz biotechnologicalbasedrecombinantproteinvaccinesdevelopedagainsttoxoplasmosis AT aysudegirmencidoskaya biotechnologicalbasedrecombinantproteinvaccinesdevelopedagainsttoxoplasmosis |